Goodwin Biotechnology and Rafagen Ink Deal for Biomanufacturing and Cell-Line Development
Rafagen's gene-expression systems use FACS-aided and nonantibody-based technology.!--h2>
Goodwin Biotechnology (GBI), a contract biomanufacturing company, and Rafagen, a provider of engineered cell lines for protein and mAb production,are joining forces. Their collaborative agreement covers cell line engineering and biological contract manufacturing.
"By collaborating with Rafagen for cell-line engineering, we at GBI can expand our capabilities as a biological contract manufacturing organization and offer one-stop shopping," comments SooYoung Lee, Ph.D., svp at GBI.
"This enables our clients to overcome challenging projects by working from their cDNA to develop more robust and high-productivity cell lines that will not only scale up with greater efficiency, but by identifying cell lines with the highest level of efficacy, the end product will hopefully optimize patient outcomes," Dr. Lee says.
Rafagen develops and commercializes gene-expression systems. The company uses FACS-aided and nonantibody-based technology for the selection of highly expressing cell lines. “The highest producing cell lines will be established at a fraction of the time currently required," states Sung Ho Hahm, Ph.D., co-founder and president / CEO of Ragagen.